Epigenic Therapeutics to Present Company's Epigenetic Modulation Technology in Enhancement of CAR-T Function at SITC 2023
Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced to present a poster at The Society for Immunotherapy of Cancer（SITC）38th Annual Meeting on November 1-5 at California. The poster is entitled “Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy" (Abstract Number: 58).
EPIREGTM technology, Epigenic’s core epigenetic regulation technology, offers a compelling alternative to the traditional cleavage-dependent gene editing tools by which altering the DNA sequence would raise safety concerns. By precisely modulating gene expression(s) at epigenetic levels, EPIREGTM is expected to achieve potent and durable silencing of target gene(s) to provide revolutionary and novel solutions to patients with cancer and chronic diseases.
The poster demonstrated that EPIREGTM enhances CAR-T therapy by an epigenetic solution that addresses Cas9-induced chromosomal aberrations without DNA cleavage. Modulation of immune check point genes leads to elevation of CAR expression and stemness as well as enhancement of CAR-T cell functionality and ultimately in vivo anti-tumor potency. EPIREGTM provides the potential as a potent, durable, and safe strategy for future of CAR-T cell therapy.
About Epigenic Therapeutics
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases. For more information, visit www.epigenictx.com
Contact
Partnering@epigenictx.com
Media@epigenictx.com
Investors@epigenictx.com
